Corcept Therapeutics (CORT)
Corcept Therapeutics (CORT) Stock Price, Analysis & Data
No hay datos disponibles
| Precio de compra | 109.92 |
| Capitalización de mercado | 13.03B |
| Ingresos (TTM) | 830.81M |
| Beneficio neto (TTM) | 54.27M |
| Beta | 0.46 |
| EPS (TTM) | 0.45 |
| Ratio PER (TTM) | 267.78 |
| Adelante PE | 27.37 |
| P/B (TTM) | 18.43 |
| P/S (TTM) | 15.68 |
| Earnings Date | Nov 4, 2026 |
| Precio de venta | 116.64 |
| Volumen | 776,197 |
| Volumen medio (20D) | 1,108,004 |
| Abierto | 116.59 |
| Anterior Cerrar | 117.17 |
| Rango del día | 116.59 - 119.95 |
| Rango de 52 semanas | 28.66 - 122.21 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de CORT
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have...
Desempeño financiero
En 2025, los ingresos de Corcept Therapeutics fueron 761.41M, un aumento de 12.79% en comparación con 675.04M del año anterior. Las ganancias fueron 99.65M, una disminución de -29.43%.
Estados financierosSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
1 semana hace · Simply Wall St.
Corcept Therapeutics (CORT) Stock May Trade At A Discount Yet A Premium On SalesCorcept Therapeutics stock has delivered a very strong run over the past few years, yet its low overall value score suggests the current share price may already reflect a lot of optimism. After such a...
